Volumetric Reduction of Brain Metastases After Stereotactic Radiotherapy: Prognostic Factors and Effect on Local Control

Overview

Journal Cancer Med

Specialty Oncology

Date 2022 May 10

PMID 35535485

Authors

Naoyuki Kanayama

Toshiki Ikawa

Shingo Ohira

Takero Hirata

Masahiro Morimoto

Kazuhiko Ogawa

Teruki Teshima

Koji Konishi

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: Few reports include volumetric measurements as endpoints after stereotactic radiotherapy (SRT) despite the importance of such measurements. This study aimed to (1) investigate the impact of the volumetric response (specifically, an over 65% and over 90% volume reduction in brain metastases) at 6 months post-SRT on local control and (2) identify the predictive factors for a volumetric response of over 65% and over 90%.

Materials And Methods: This study included 250 unresected brain metastases (>0.3 cc) treated with SRT. Doses were stratified according to the biological effective dose (BED). The BED was calculated using four models: linear-quadratic (LQ): α/β = 10; LQ: α/β = 20; LQ cubic: α/β = 12; and LQ linear: α/β = 10. The median prescription dose was 30 Gy/3 fractions (BED20, 45). The median follow-up time after SRT was 18.6 months (range, 6.4-81.8 months).

Results: In the multivariate analysis, over 65% volume reduction and over 90% volume reduction were prognostic factors for local control (hazard ratio: 2.370, p = 0.011 and hazard ratio: 3.161, p = 0.014, respectively). A dose of 80% of the gross tumor volume (GTV) D80 > BED20 58 was a predictive factor for over 65% and over 90% volume reductions (odds ratio: 1.975, p = 0.023; odds ratio: 3.204, p < 0.001, respectively).

Conclusion: Robust volume reduction of brain metastases at 6 months post-SRT can predict local control. GTV D80 in the LQ model: α/β = 20 may be warranted for good volume reduction.

Citing Articles

Effects of Institutional Experience on Plan Quality in Stereotactic Radiotherapy Using HyperArc for Brain Metastases.

Kihara S, Ohira S, Kanayama N, Ikawa T, Inui S, Isono M In Vivo. 2024; 39(1):210-217.

PMID: 39740907 PMC: 11705131. DOI: 10.21873/invivo.13819.

Magnetic Resonance Imaging Assessment of Morphological Changes and Molecular Behavior to Evaluate Treatment Response of Brain Metastatic Lesions After Stereotactic Radiosurgery.

Garcia-Rizk J, Ortiz Haro M, Santos Aragon L, de la Mata-Moya D, Hernandez Bojorquez M Cureus. 2024; 16(11):e73630.

PMID: 39677170 PMC: 11645163. DOI: 10.7759/cureus.73630.

Consideration of Optimal Evaluation Metrics for Internal Gross Tumor Dose Relevant to Tumor Response in Multi-fraction Stereotactic Radiosurgery of Brain Metastasis.

Ohtakara K, Suzuki K Cureus. 2024; 16(7):e65338.

PMID: 39184769 PMC: 11344629. DOI: 10.7759/cureus.65338.

Multifraction stereotactic radiotherapy utilizing inhomogeneous dose distribution for brainstem metastases: a single-center retrospective analysis.

Ikawa T, Kanayama N, Arita H, Takano K, Sakai M, Morimoto M J Radiat Res. 2024; 65(5):658-666.

PMID: 39154372 PMC: 11420839. DOI: 10.1093/jrr/rrae057.

Association of increasing gross tumor volume dose with tumor volume reduction and local control in fractionated stereotactic radiosurgery for unresected brain metastases.

Kanayama N, Ikawa T, Takano K, Arita H, Morimoto M, Hirata T Radiat Oncol. 2024; 19(1):95.

PMID: 39061079 PMC: 11282845. DOI: 10.1186/s13014-024-02487-6.

References

Abraham C, Garsa A, Badiyan S, Drzymala R, Yang D, DeWees T . Internal dose escalation is associated with increased local control for non-small cell lung cancer (NSCLC) brain metastases treated with stereotactic radiosurgery (SRS). Adv Radiat Oncol. 2018; 3(2):146-153. PMC: 6000027. DOI: 10.1016/j.adro.2017.11.003. View

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

Miller A, Hoogstraten B, STAQUET M, Winkler A . Reporting results of cancer treatment. Cancer. 1981; 47(1):207-14. DOI: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. View

Guerrero M, Li X . Extending the linear-quadratic model for large fraction doses pertinent to stereotactic radiotherapy. Phys Med Biol. 2004; 49(20):4825-35. DOI: 10.1088/0031-9155/49/20/012. View

Kraft J, van Timmeren J, Mayinger M, Frei S, Borsky K, Sabrina Stark L . Distance to isocenter is not associated with an increased risk for local failure in LINAC-based single-isocenter SRS or SRT for multiple brain metastases. Radiother Oncol. 2021; 159:168-175. DOI: 10.1016/j.radonc.2021.03.022. View

Steinmann D, Vordermark D, Gerstenberg W, Aschoff R, Gharbi N, Muller A . Quality of life in patients with limited (1-3) brain metastases undergoing stereotactic or whole brain radiotherapy : A prospective study of the DEGRO QoL working group. Strahlenther Onkol. 2019; 196(1):48-57. DOI: 10.1007/s00066-019-01506-w. View

Redmond K, Gui C, Benedict S, Milano M, Grimm J, Vargo J . Tumor Control Probability of Radiosurgery and Fractionated Stereotactic Radiosurgery for Brain Metastases. Int J Radiat Oncol Biol Phys. 2021; 110(1):53-67. DOI: 10.1016/j.ijrobp.2020.10.034. View

Bauknecht H, Romano V, Rogalla P, Klingebiel R, Wolf C, Bornemann L . Intra- and interobserver variability of linear and volumetric measurements of brain metastases using contrast-enhanced magnetic resonance imaging. Invest Radiol. 2009; 45(1):49-56. DOI: 10.1097/RLI.0b013e3181c02ed5. View

Alongi F, Nicosia L, Figlia V, Giaj-Levra N, Cuccia F, Mazzola R . Long-term disease outcome and volume-based decision strategy in a large cohort of multiple brain metastases treated with a mono-isocentric linac-based Stereotactic Radiosurgery technique. Clin Transl Oncol. 2021; 23(8):1561-1570. DOI: 10.1007/s12094-020-02550-0. View

10.

Gago-Arias A, Neira S, Pombar M, Gomez-Caamano A, Pardo-Montero J . Evaluation of indirect damage and damage saturation effects in dose-response curves of hypofractionated radiotherapy of early-stage NSCLC and brain metastases. Radiother Oncol. 2021; 161:1-8. DOI: 10.1016/j.radonc.2021.05.012. View

11.

Sharpton S, Oermann E, Moore D, Schreiber E, Hoffman R, Morris D . The volumetric response of brain metastases after stereotactic radiosurgery and its post-treatment implications. Neurosurgery. 2013; 74(1):9-15. DOI: 10.1227/NEU.0000000000000190. View

12.

Kano H, Kondziolka D, Lobato-Polo J, Zorro O, Flickinger J, Lunsford L . T1/T2 matching to differentiate tumor growth from radiation effects after stereotactic radiosurgery. Neurosurgery. 2010; 66(3):486-91. DOI: 10.1227/01.NEU.0000360391.35749.A5. View

13.

Wiggenraad R, Verbeek-de Kanter A, Kal H, Taphoorn M, Vissers T, Struikmans H . Dose-effect relation in stereotactic radiotherapy for brain metastases. A systematic review. Radiother Oncol. 2011; 98(3):292-7. DOI: 10.1016/j.radonc.2011.01.011. View

14.

Kennedy W, DeWees T, Acharya S, Mahmood M, Knutson N, Goddu S . Internal dose escalation associated with increased local control for melanoma brain metastases treated with stereotactic radiosurgery. J Neurosurg. 2020; 135(3):855-861. DOI: 10.3171/2020.7.JNS192210. View

15.

Lucia F, Key S, Dissaux G, Goasduff G, Lucia A, Ollivier L . Inhomogeneous tumor dose distribution provides better local control than homogeneous distribution in stereotactic radiotherapy for brain metastases. Radiother Oncol. 2018; 130:132-138. DOI: 10.1016/j.radonc.2018.06.039. View

16.

Kim W, Kim D, Han J, Paek S, Chung H, Park C . Early significant tumor volume reduction after radiosurgery in brain metastases from renal cell carcinoma results in long-term survival. Int J Radiat Oncol Biol Phys. 2011; 82(5):1749-55. DOI: 10.1016/j.ijrobp.2011.03.044. View

17.

Ohira S, Ueda Y, Kanayama N, Isono M, Inui S, Komiyama R . Impact of Multileaf Collimator Width on Dose Distribution in HyperArc Fractionated Stereotactic Irradiation for Multiple (-) Brain Metastases. Anticancer Res. 2021; 41(6):3153-3159. DOI: 10.21873/anticanres.15101. View

18.

Yomo S, Oguchi K . Prospective study of C-methionine PET for distinguishing between recurrent brain metastases and radiation necrosis: limitations of diagnostic accuracy and long-term results of salvage treatment. BMC Cancer. 2017; 17(1):713. PMC: 5674753. DOI: 10.1186/s12885-017-3702-x. View

19.

Kanayama N, Ikawa T, Ohira S, Hirata T, Morimoto M, Ogawa K . Volumetric reduction of brain metastases after stereotactic radiotherapy: Prognostic factors and effect on local control. Cancer Med. 2022; 11(24):4806-4815. PMC: 9761087. DOI: 10.1002/cam4.4809. View

20.

Matsuyama T, Kogo K, Oya N . Clinical outcomes of biological effective dose-based fractionated stereotactic radiation therapy for metastatic brain tumors from non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2012; 85(4):984-90. DOI: 10.1016/j.ijrobp.2012.09.008. View